Literature DB >> 18558435

The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.

Leif Carlsson1.   

Abstract

Current guidelines describe strategies on how the potential of non-antiarrhythmic drugs to delay ventricular repolarisation should be assessed. However, the non-clinical guidelines recommend repolarisation assays only and do not advocate experimental models that express the proarrhythmia of concern, torsades de pointes (TdP). Although the repolarisation assays may predict QT interval prolongation in man they cannot alone sufficiently predict proarrhythmia risk. Furthermore, there is also a need for more robust surrogate markers of drug-induced proarrhythmia and such validated markers are on the horizon as a result of the availability of sensitive animal models of TdP. This review will describe the methoxamine-sensitised rabbit model of TdP, one of the most frequently used proarrhythmia models, and present some of it characteristics, its pros and cons and how it historically has been used for assessing proarrhythmia liability of drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558435     DOI: 10.1016/j.pharmthera.2008.04.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  9 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Towards a better understanding of QT interval variability.

Authors:  Larisa G Tereshchenko; Ronald D Berger
Journal:  Ther Adv Drug Saf       Date:  2011-12

4.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced Torsade de Pointes.

Authors:  Mihoko Hagiwara; Seiji Shibuta; Kazuhiro Takada; Ryuichi Kambayashi; Misako Nakajo; Megumi Aimoto; Yoshinobu Nagasawa; Akira Takahara
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

6.  Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.

Authors:  Heather J Finlay; James A Johnson; John L Lloyd; Ji Jiang; James Neels; Prashantha Gunaga; Abhisek Banerjee; Naveen Dhondi; Anjaneya Chimalakonda; Sandhya Mandlekar; Mary Lee Conder; Harinath Sale; Dezhi Xing; Paul Levesque; Ruth R Wexler
Journal:  ACS Med Chem Lett       Date:  2016-06-09       Impact factor: 4.345

Review 7.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 8.  Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.

Authors:  Hugo M Vargas; Michael G Rolf; Todd A Wisialowski; William Achanzar; Anthony Bahinski; Alan Bass; Charles T Benson; Khuram W Chaudhary; Nicolas Couvreur; Corina Dota; Michael J Engwall; C Michael Foley; David Gallacher; Andrea Greiter-Wilke; Jean-Michel Guillon; Brian Guth; Herbert M Himmel; Christa Hegele-Hartung; Maki Ito; Stephen Jenkinson; Katsuyoshi Chiba; Armando Lagrutta; Paul Levesque; Eric Martel; Yoshiko Okai; Ravikumar Peri; Amy Pointon; Yusheng Qu; Ard Teisman; Martin Traebert; Takashi Yoshinaga; Gary A Gintant; Derek J Leishman; Jean-Pierre Valentin
Journal:  Clin Pharmacol Ther       Date:  2020-09-24       Impact factor: 6.875

Review 9.  Update on ICH E14/S7B Cardiac Safety Regulations: The Expanded Role of Preclinical Assays and the "Double-Negative" Scenario.

Authors:  Robert M Lester
Journal:  Clin Pharmacol Drug Dev       Date:  2021-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.